Global Pharma Organizations Back Turn Biotechnologies To Advance Its Cell Rejuvenation Program
By asianet
– Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio’s preclinical advances in multiple therapeutic areas Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that it closed an oversubscribed fundraising round to support the next stage … Continued